Journal profile · PHARMACOLOGY & PHARMACY
Expert Review of Clinical Pharmacology
ISSN 1751-2433 · eISSN 1751-2441 · Taylor and Francis Ltd. · ENGLAND
Expert Review of Clinical Pharmacology: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.8; subscription journal; median 77 days to acceptance (103 articles, last 24 months); 95 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Expert Review of Clinical Pharmacology is published by Taylor and Francis Ltd. and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Diabetes Treatment and Management, Health Systems, Economic Evaluations, Quality of Life and Pharmaceutical studies and practices, together about 21.3% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery. Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.
Source: LetPub
Research area (LetPub): PHARMACOLOGY & PHARMACY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Diabetes Treatment and ManagementMedicine9.1%
- Health Systems, Economic Evaluations, Quality of LifeEconomics, Econometrics and Finance6.2%
- Pharmaceutical studies and practicesMedicine6%
- Pharmacogenetics and Drug MetabolismPharmacology, Toxicology and Pharmaceutics5.6%
- Pharmacological Effects and Toxicity StudiesMedicine5.1%
- Pharmaceutical Practices and Patient OutcomesMedicine4.5%
- Antibiotics Pharmacokinetics and EfficacyMedicine4.5%
- Asthma and respiratory diseasesMedicine4.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.8LetPub ·
- CiteScore 2026-06
- 5.9LetPub ·
- SJR 2026-06
- 0.85LetPub ·
- SNIP 2026-06
- 0.95LetPub ·
- h-index
- 32LetPub ·
- h-index
- 83OpenAlex ·
- i10-index
- 1,036OpenAlex ·
- 2-year mean citedness
- 3.49OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 4.09%LetPub ·
Volume
- Articles per year
- 84LetPub ·
Articles by year OpenAlex count · 1,941 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 74 | 26 | 23 |
| 2025 | 95 | 26 | 254 |
| 2024 | 103 | 44 | 672 |
| 2023 | 115 | 37 | 1,196 |
| 2022 | 132 | 43 | 1,680 |
| 2021 | 128 | 37 | 3,165 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
77 daysMedian, submission to acceptance · P25–P75 59 days – 103 days
- Acceptance to online
- median 8 days (103 articles)
- Submission to online
- median 90 days
- Sample
- 103 articles with submission and acceptance dates (198 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Taylor and Francis Ltd.
- Country or region
- ENGLAND
- Language
- English
- ISSN
- 1751-2433
- Electronic ISSN
- 1751-2441
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Expert Review of Clinical Pharmacology
What CAS zone is Expert Review of Clinical Pharmacology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Expert Review of Clinical Pharmacology is in Zone 3 of Medicine, and in Zone 3 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Expert Review of Clinical Pharmacology?
The latest impact factor listed by LetPub is 3.8; CiteScore 5.9, h-index 83.
How long does peer review take at Expert Review of Clinical Pharmacology?
Based on the dates recorded on 103 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 77 days (interquartile range 59–103 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Expert Review of Clinical Pharmacology?
According to LetPub and DOAJ records, Expert Review of Clinical Pharmacology is indexed in SCIE and Scopus.
Is Expert Review of Clinical Pharmacology open access, and what is the APC?
Expert Review of Clinical Pharmacology is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .